RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) has initiated its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral® Amphotericin B. This study represents a significant step forward in the evaluation of BDSI’s second drug delivery platform, known as Bioral®.
